Monogenic obesity; using drugs to bypass the problem

Thumbnail
View / Open Files
Authors
Coll, anthony
Publication Date
2018-07-03
Journal Title
Cell Metabolism
ISSN
1550-4131
Publisher
Elsevier
Volume
28
Issue
1
Pages
1-2
Type
Article
Metadata
Show full item record
Citation
Coll, a. (2018). Monogenic obesity; using drugs to bypass the problem. Cell Metabolism, 28 (1), 1-2. https://doi.org/10.1016/j.cmet.2018.06.015
Abstract
Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue, Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.
Keywords
Body Weight, Glucagon-Like Peptide-1 Receptor, Humans, Mutation, Obesity, Receptor, Melanocortin, Type 4
Sponsorship
A.P.C. is supported by the Medical Research Council (MRC Metabolic Diseases Unit [MRC_MC_UU_12012/1]).
Funder references
Medical Research Council (MC_UU_12012/1)
Medical Research Council (MC_UU_12012/5)
Identifiers
External DOI: https://doi.org/10.1016/j.cmet.2018.06.015
This record's URL: https://www.repository.cam.ac.uk/handle/1810/283544
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Statistics



Total file downloads (since January 2020). For more information on metrics see the IRUS guide.